Summary

In-vitro Transcription Templates Market – Scope of Report
TMR’s report on the global in-vitro transcription templates market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global in-vitro transcription templates market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global in-vitro transcription templates market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the in-vitro transcription templates market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global in-vitro transcription templates market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global in-vitro transcription templates market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global in-vitro transcription templates market.

The report delves into the competitive landscape of the global in-vitro transcription templates market. Key players operating in the global in-vitro transcription templates market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global in-vitro transcription templates market profiled in this report.

Key Questions Answered in Global in-vitro transcription templates Market Report
• What is the sales/revenue generated by in-vitro transcription templates across all regions during the forecast period?
• What are the opportunities in the global in-vitro transcription templates market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

In-vitro Transcription Templates Market – Research Objectives and Research Approach
The comprehensive report on the global in-vitro transcription templates market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global in-vitro transcription templates market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global in-vitro transcription templates market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global In-vitro Transcription Templates Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global In-vitro Transcription Templates Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global In-vitro Transcription Templates Market Analysis and Forecast, by Disease
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Disease, 2017–2031
6.3.1. Cancer
6.3.1.1. Solid Tumors
6.3.1.2. Colorectal Cancer
6.3.1.3. NSCLC
6.3.1.4. Melanoma
6.3.1.5. Leukemia
6.3.1.6. Prostate Cancer
6.3.1.7. Others
6.3.2. Infectious Diseases
6.3.2.1. Influenza
6.3.2.2. COVID-19
6.3.2.3. AIDS
6.3.2.4. Others
6.3.3. Lifestyle Diseases
6.3.4. Genetic Diseases
6.3.5. Others
6.4. Market Attractiveness, by Disease
7. Global In-vitro Transcription Templates Market Analysis and Forecast, by Treatment
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Treatment, 2017–2031
7.3.1. Vaccine
7.3.2. Therapeutic
7.3.3. 7.4 Market Attractiveness, by Treatment
8. Global In-vitro Transcription Templates Market Analysis and Forecast, by Research Stage
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Research Stage, 2017–2031
8.3.1. Exploratory
8.3.2. Clinical
8.4. Market Attractiveness, by Research Stage
9. Global In-vitro Transcription Templates Market Analysis and Forecast, by End-user
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by End-user, 2017–2031
9.3.1. Pharmaceutical & Biotechnology Companies
9.3.2. CROs & CMOs
9.3.3. Academics & Research
9.3.4. Others
9.4. Market Attractiveness, by End-user
10. Global In-vitro Transcription Templates Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region, 2017–2031
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
10.3. Market Attractiveness, by Region
11. North America In-vitro Transcription Templates Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Disease, 2017–2031
11.2.1. Cancer
11.2.1.1. Solid Tumors
11.2.1.2. Colorectal Cancer
11.2.1.3. NSCLC
11.2.1.4. Melanoma
11.2.1.5. Leukemia
11.2.1.6. Prostate Cancer
11.2.1.7. Others
11.2.2. Infectious Diseases
11.2.2.1. Influenza
11.2.2.2. COVID-19
11.2.2.3. AIDS
11.2.2.4. Others
11.2.3. Lifestyle Diseases
11.2.4. Genetic Diseases
11.2.5. Others
11.3. Market Attractiveness, by Disease
11.4. Market Value Forecast, by Treatment, 2017–2031
11.4.1. Vaccine
11.4.2. Therapeutic
11.5. Market Attractiveness, by Treatment
11.6. Market Value Forecast, by Research Stage, 2017–2031
11.6.1. Exploratory
11.6.2. Clinical
11.7. Market Attractiveness, by Research Stage
11.8. Market Value Forecast, by End-user, 2017–2031
11.8.1. Pharmaceutical & Biotechnology Companies
11.8.2. CROs & CMOs
11.8.3. Academics & Research
11.8.4. Others
11.9. Market Attractiveness, by End-user
11.10. Market Value Forecast, by Country/Sub-region, 2017–2031
11.10.1. U.S.
11.10.2. Canada
11.11. Market Attractiveness Analysis
11.11.1. By Disease
11.11.2. By Treatment
11.11.3. By Research Stage
11.11.4. By End-user
11.11.5. By Country
12. Europe In-vitro Transcription Templates Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Disease, 2017–2031
12.2.1. Cancer
12.2.1.1. Solid Tumors
12.2.1.2. Colorectal Cancer
12.2.1.3. NSCLC
12.2.1.4. Melanoma
12.2.1.5. Leukemia
12.2.1.6. Prostate Cancer
12.2.1.7. Others
12.2.2. Infectious Diseases
12.2.2.1. Influenza
12.2.2.2. COVID-19
12.2.2.3. AIDS
12.2.2.4. Others
12.2.3. Lifestyle Diseases
12.2.4. Genetic Diseases
12.2.5. Others
12.3. Market Attractiveness, by Disease
12.4. Market Value Forecast, by Treatment, 2017–2031
12.4.1. Vaccine
12.4.2. Therapeutic
12.5. Market Attractiveness, by Treatment
12.6. Market Value Forecast, by Research Stage, 2017–2031
12.6.1. Exploratory
12.6.2. Clinical
12.7. Market Attractiveness, by Research Stage
12.8. Market Value Forecast, by End-user, 2017–2031
12.8.1. Pharmaceutical & Biotechnology Companies
12.8.2. CROs & CMOs
12.8.3. Academics & Research
12.8.4. Others
12.9. Market Attractiveness, by End-user
12.10. Market Value Forecast, by Country/Sub-region, 2017–2031
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Market Attractiveness Analysis
12.11.1. By Disease
12.11.2. By Treatment
12.11.3. By Research Stage
12.11.4. By End-user
12.11.5. By Country/Sub-region
13. Asia Pacific In-vitro Transcription Templates Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Disease, 2017–2031
13.2.1. Cancer
13.2.1.1. Solid Tumors
13.2.1.2. Colorectal Cancer
13.2.1.3. NSCLC
13.2.1.4. Melanoma
13.2.1.5. Leukemia
13.2.1.6. Prostate Cancer
13.2.1.7. Others
13.2.2. Infectious Diseases
13.2.2.1. Influenza
13.2.2.2. COVID-19
13.2.2.3. AIDS
13.2.2.4. Others
13.2.3. Lifestyle Diseases
13.2.4. Genetic Diseases
13.2.5. Others
13.3. Market Attractiveness, by Disease
13.4. Market Value Forecast, by Treatment, 2017–2031
13.4.1. Vaccine
13.4.2. Therapeutic
13.5. Market Attractiveness, by Treatment
13.6. Market Value Forecast, by Research Stage, 2017–2031
13.6.1. Exploratory
13.6.2. Clinical
13.7. Market Attractiveness, by Research Stage
13.8. Market Value Forecast, by End-user, 2017–2031
13.8.1. Pharmaceutical & Biotechnology Companies
13.8.2. CROs & CMOs
13.8.3. Academics & Research
13.8.4. Others
13.9. Market Attractiveness, by End-user
13.10. Market Value Forecast, by Country/Sub-region, 2017–2031
13.10.1. China
13.10.2. Japan
13.10.3. India
13.10.4. Australia & New Zealand
13.10.5. Rest of Asia Pacific
13.11. Market Attractiveness Analysis
13.11.1. By Disease
13.11.2. By Treatment
13.11.3. By Research Stage
13.11.4. By End-user
13.11.5. By Country/Sub-region
14. Latin America In-vitro Transcription Templates Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Disease, 2017–2031
14.2.1. Cancer
14.2.1.1. Solid Tumors
14.2.1.2. Colorectal Cancer
14.2.1.3. NSCLC
14.2.1.4. Melanoma
14.2.1.5. Leukemia
14.2.1.6. Prostate Cancer
14.2.1.7. Others
14.2.2. Infectious Diseases
14.2.2.1. Influenza
14.2.2.2. COVID-19
14.2.2.3. AIDS
14.2.2.4. Others
14.2.3. Lifestyle Diseases
14.2.4. Genetic Diseases
14.2.5. Others
14.3. Market Attractiveness, by Disease
14.4. Market Value Forecast, by Treatment, 2017–2031
14.4.1. Vaccine
14.4.2. Therapeutic
14.5. Market Attractiveness, by Treatment
14.6. Market Value Forecast, by Research Stage, 2017–2031
14.6.1. Exploratory
14.6.2. Clinical
14.7. Market Attractiveness, by Research Stage
14.8. Market Value Forecast, by End-user, 2017–2031
14.8.1. Pharmaceutical & Biotechnology Companies
14.8.2. CROs & CMOs
14.8.3. Academics & Research
14.8.4. Others
14.9. Market Attractiveness, by End-user
14.10. Market Value Forecast, by Country/Sub-region, 2017–2031
14.10.1. Brazil
14.10.2. Mexico
14.10.3. Rest of Latin America
14.11. Market Attractiveness Analysis
14.11.1. By Disease
14.11.2. By Treatment
14.11.3. By Research Stage
14.11.4. By End-user
14.11.5. By Country/Sub-region
15. Middle East & Africa In-vitro Transcription Templates Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Disease, 2017–2031
15.2.1. Cancer
15.2.1.1. Solid Tumors
15.2.1.2. Colorectal Cancer
15.2.1.3. NSCLC
15.2.1.4. Melanoma
15.2.1.5. Leukemia
15.2.1.6. Prostate Cancer
15.2.1.7. Others
15.2.2. Infectious Diseases
15.2.2.1. Influenza
15.2.2.2. COVID-19
15.2.2.3. AIDS
15.2.2.4. Others
15.2.3. Lifestyle Diseases
15.2.4. Genetic Diseases
15.2.5. Others
15.3. Market Attractiveness, by Disease
15.4. Market Value Forecast, by Treatment, 2017–2031
15.4.1. Vaccine
15.4.2. Therapeutic
15.5. Market Attractiveness, by Treatment
15.6. Market Value Forecast, by Research Stage, 2017–2031
15.6.1. Exploratory
15.6.2. Clinical
15.7. Market Attractiveness, by Research Stage
15.8. Market Value Forecast, by End-user, 2017–2031
15.8.1. Pharmaceutical & Biotechnology Companies
15.8.2. CROs & CMOs
15.8.3. Academics & Research
15.8.4. Others
15.9. Market Attractiveness, by End-user
15.10. Market Value Forecast, by Country/Sub-region, 2017–2031
15.10.1. GCC Countries
15.10.2. South Africa
15.10.3. Rest of Middle East & Africa
15.11. Market Attractiveness Analysis
15.11.1. By Disease
15.11.2. By Treatment
15.11.3. By Research Stage
15.11.4. By End-user
15.11.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Player – Competition Matrix (By Tier and Size of Companies)
16.2. Market Share Analysis, by Company (2022)
16.3. Company Profiles
16.3.1. Thermo Fisher Scientific Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Promega Corporation
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. Agilent Technologies, Inc.
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. New England Biolabs
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Takara Bio Inc.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. LGC Limited
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Enzynomics Co. Ltd.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Enzo Life Sciences, Inc.
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Danaher Corporation
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview